Brevan Howard Capital Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.62M Buy
82,435
+2,857
+4% +$149K 0.03% 362
2026
Q1
$3.82M Buy
+79,578
New +$3.49M 0.03% 336
2024
Q1
Sell
-14,107
Closed -$396K 1306
2023
Q4
$396K Buy
+14,107
New +$388K ﹤0.01% 591

Other funds holding RPRX

Brevan Howard Capital Management's RPRX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Royalty Pharma (RPRX) stake by 3.6% in Q2 2026, buying an estimated $149K and bringing the position to 82,435 shares worth $4.62M. The position accounts for 0.03% of the portfolio, ranked #362.

Brevan Howard Capital Management first reported a position in RPRX in Q4 2023 and has held it in 3 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Brevan Howard Capital Management held 82,435 shares of Royalty Pharma worth $4.62M as of Q2 2026.
  • Brevan Howard Capital Management bought 2,857 Royalty Pharma shares in Q2 2026, an estimated $149K.
  • Royalty Pharma made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #362 holding.
  • Brevan Howard Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 3 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.